Toxicology – Class IA Antidysrhythmics: Quinidine and Disopyramide

Core Concept

Quinidine and disopyramide are Class IA sodium-channel-blocking antidysrhythmics. Their use has declined substantially because safer or more effective alternatives are available for many arrhythmias.

In overdose, the major dangers are:

• Fast sodium-channel blockade → QRS widening
• Potassium-channel blockade → QT prolongation
• Ventricular dysrhythmias
• Torsades de pointes
• Hypotension
• Bradycardia/AV block
• Seizures and CNS depression

Quinidine additionally produces cinchonism, while disopyramide has particularly prominent antimuscarinic and negative-inotropic effects.

There is no specific antidote.

⸻

Mechanism – Class IA

Class IA agents block fast myocardial sodium channels.

This slows phase-0 depolarization:

Na⁺-channel blockade → slowed conduction → QRS widening

They also inhibit repolarizing potassium currents:

K⁺-channel blockade → prolonged repolarization → QT prolongation

Thus, Class IA poisoning can produce the dangerous combination of:

Wide QRS + prolonged QT

⸻

Electrophysiologic Effects

Toxicity may cause:

• Slowed atrial conduction
• Slowed AV/intraventricular conduction
• QRS widening
• QT prolongation
• Bradyarrhythmias
• Ventricular tachycardia
• Ventricular fibrillation
• Torsades de pointes

These abnormalities may deteriorate rapidly.

⸻

Quinidine

Quinidine is closely related to quinine.

In addition to sodium- and potassium-channel effects, it can produce:

• α-adrenergic blockade
• Hypotension
• GI symptoms
• Cinchonism

Its role in contemporary rhythm management is much narrower than suggested by older toxicology texts.

⸻

Disopyramide

Disopyramide has important:

• Sodium-channel-blocking activity
• Potassium-channel effects
• Antimuscarinic activity
• Negative inotropic effects

Consequently, toxicity can include:

• Dry mouth
• Mydriasis
• Urinary retention
• Ileus
• Tachycardia
• Delirium
• Hypotension
• Heart failure/cardiogenic shock
• Conduction abnormalities

⸻

Toxic Dose

There is no reliable universal toxic-dose threshold.

Toxicity can occur relatively close to therapeutic concentrations, especially when clearance is impaired or interacting medications are present.

Risk depends on:

• Agent
• Formulation
• Amount
• Renal/hepatic function
• Baseline conduction disease
• Electrolytes
• Drug interactions
• Coingestants

Clinical status and serial ECG findings are more important than the reported dose alone.

⸻

Sustained-Release Preparations

Modified-release formulations can produce:

• Delayed absorption
• Delayed peak toxicity
• Prolonged cardiotoxicity

Antimuscarinic slowing of GI motility may further delay absorption.

An initially normal ECG therefore does not necessarily exclude later deterioration after a substantial sustained-release exposure.

⸻

Cinchonism

Quinidine can produce a syndrome known as cinchonism.

Possible manifestations include:

• Tinnitus
• Hearing disturbance
• Headache
• Dizziness
• Nausea/vomiting
• Visual disturbance
• Confusion

More severe toxicity may cause marked visual impairment and serious neurologic or cardiovascular abnormalities.

Sudden tinnitus or visual symptoms in a patient taking quinidine should raise concern for toxicity.

⸻

Neurologic Toxicity

Severe poisoning may produce:

• Confusion
• Somnolence
• Seizures
• Coma
• Respiratory depression

Seizures can worsen cardiotoxicity through:

Seizure → lactic acidosis → acidemia → increased sodium-channel toxicity

Rapid seizure control is therefore important.

⸻

Cardiovascular Toxicity

Major manifestations include:

• QRS widening
• QT prolongation
• AV conduction delay
• Bradycardia
• Hypotension
• Ventricular tachycardia
• Ventricular fibrillation
• Torsades de pointes

Severe poisoning can progress to shock or cardiac arrest.

⸻

Why Hypotension Occurs

Hypotension may result from several simultaneous mechanisms:

• Myocardial depression
• Sodium-channel blockade
• Dysrhythmia
• α-adrenergic blockade, particularly with quinidine
• Negative inotropy, particularly with disopyramide
• Acidemia

Therefore, treatment must address both circulation and the underlying electrical toxicity.

⸻

ECG – Essential Test

Obtain an ECG promptly in suspected significant poisoning.

Assess:

• Heart rate
• Rhythm
• PR interval
• QRS duration
• QT/QTc
• AV conduction
• Ventricular ectopy

Symptomatic or significant exposures require continuous cardiac monitoring.

⸻

QRS Widening

QRS widening reflects myocardial sodium-channel blockade.

Increasing QRS duration suggests increasing conduction toxicity and greater risk of ventricular dysrhythmia.

The ECG and clinical trajectory are more useful than a serum drug concentration for acute management.

⸻

QT Prolongation

Class IA agents delay ventricular repolarization.

This produces:

QT prolongation → early afterdepolarizations → polymorphic VT → torsades de pointes

Risk increases with:

• Hypokalemia
• Hypomagnesemia
• Bradycardia
• Other QT-prolonging drugs
• Congenital long-QT susceptibility

⸻

Quinidine and Diarrhea

Quinidine commonly causes gastrointestinal adverse effects, including diarrhea.

Significant diarrhea can cause:

K⁺ loss → hypokalemia → increased QT-related dysrhythmia risk

Thus electrolyte abnormalities can convert otherwise modest drug exposure into a more dangerous electrophysiologic situation.

⸻

Syncope

Syncope in a patient receiving a QT-prolonging Class IA agent should prompt urgent consideration of a transient ventricular dysrhythmia, including torsades.

However, it should not be assumed automatically; other causes of syncope still require evaluation.

⸻

Laboratory Evaluation

Important tests in significant poisoning include:

• Potassium
• Magnesium
• Calcium
• Bicarbonate
• Creatinine
• Glucose

Severe cases may additionally require:

• Blood gas
• Lactate
• Renal and hepatic assessment

Renal function is particularly relevant to drugs with substantial renal elimination.

⸻

Serum Drug Concentrations

Quinidine or disopyramide concentrations may occasionally provide supportive information, but they generally do not determine emergency treatment.

Management should be guided by:

• ECG
• Blood pressure
• Mental status
• Seizures
• Perfusion
• Electrolytes

Do not delay treatment while awaiting a drug level.

⸻

Initial Management

Priorities are:

Airway/breathing → ECG → circulation → correct electrolytes → control seizures → treat conduction abnormalities/torsades

Continuous monitoring is important because deterioration can be abrupt.

⸻

Sodium Bicarbonate

Sodium bicarbonate is an important treatment when significant sodium-channel blockade is present.

Clinical indications include:

• Significant QRS widening
• Ventricular conduction toxicity
• Ventricular dysrhythmia associated with sodium-channel blockade
• Cardiovascular instability in the appropriate toxicologic context

Its effects come from:

• Sodium loading
• Alkalinization
• Reduced drug interaction with myocardial sodium channels

Treatment is guided by ECG response, hemodynamics, and acid–base/electrolyte status rather than blindly targeting a fixed dose.

⸻

Avoid Acidemia

Acidemia can intensify sodium-channel-blocker cardiotoxicity.

Therefore:

• Treat seizures promptly
• Maintain adequate ventilation
• Correct hypoperfusion
• Address severe metabolic abnormalities

Excessive alkalinization should also be avoided because it can cause clinically important electrolyte disturbances.

⸻

Torsades de Pointes

Management priorities include:

• Stop QT-prolonging drugs
• Correct hypokalemia
• Correct hypomagnesemia
• Correct other important electrolyte abnormalities
• IV magnesium
• Electrical defibrillation/cardioversion if unstable

For recurrent pause-dependent torsades associated with bradycardia, increasing the heart rate with overdrive pacing may be appropriate.

Isoproterenol has selected roles in acquired bradycardia-dependent torsades but is not appropriate for every prolonged-QT situation.

⸻

Drugs to Avoid in Torsades

Avoid adding medications that further prolong repolarization.

In particular, additional Class IA drugs are inappropriate.

Other QT-prolonging antiarrhythmics may also worsen acquired long-QT-associated torsades.

The older recommendation lists should therefore be interpreted according to the mechanism rather than memorized as isolated drug names.

⸻

Bradycardia and AV Block

Severe sodium-channel toxicity can produce:

• Bradycardia
• AV block
• Intraventricular conduction delay

Standard bradycardia measures may be attempted as clinically appropriate, but severe toxicologic conduction blockade may respond poorly.

Temporary pacing may be considered when clinically significant bradycardia or high-grade block persists despite correction of the toxicologic abnormalities.

⸻

Important Pacing Limitation

Electrical capture does not guarantee effective mechanical cardiac output in profound sodium-channel-blocker poisoning.

Therefore, pacing should not distract from:

• Sodium bicarbonate therapy
• Correction of acidemia
• Electrolyte correction
• Hemodynamic support

⸻

Hypotension

Management includes:

• Appropriate isotonic crystalloid when volume responsive
• Treatment of the dysrhythmia
• Sodium bicarbonate when sodium-channel cardiotoxicity is present
• Correction of acidemia

Persistent shock may require vasopressor therapy.

Norepinephrine is generally more appropriate than the historical routine dopamine-first approach for persistent vasodilatory hypotension.

Disopyramide-associated myocardial depression may complicate the hemodynamic picture.

⸻

Seizures

Benzodiazepines are first-line therapy.

Persistent seizures may require:

• Additional benzodiazepines
• Phenobarbital
• Appropriate anesthetic therapy for refractory status epilepticus

⸻

Phenytoin – Modern Correction

The historical recommendation to use phenytoin/fosphenytoin for refractory ventricular dysrhythmias is not part of routine modern management of Class IA poisoning.

Phenytoin itself interacts with sodium channels and can produce cardiovascular toxicity during IV administration.

It is also generally not preferred for toxicant-induced seizures.

⸻

Lidocaine

Lidocaine may have a specialist-guided role in refractory ventricular dysrhythmias caused by sodium-channel blockers after appropriate sodium bicarbonate therapy.

It should not replace bicarbonate as the fundamental treatment of significant Class IA sodium-channel toxicity.

⸻

Other Class I Antiarrhythmics

Avoid using additional Class IA agents because they can worsen:

• Sodium-channel blockade
• QRS widening
• QT prolongation
• Hypotension

Class IC sodium-channel blockers can likewise worsen conduction toxicity.

⸻

GI Decontamination

Do not induce vomiting.

Seizures, dysrhythmias, or altered consciousness may develop abruptly.

Routine gastric lavage is obsolete.

⸻

Activated Charcoal

A single dose of activated charcoal may be considered after a substantial recent oral exposure when:

• The drug is adsorbable
• The airway is safe
• Aspiration risk is acceptable

It should never delay cardiovascular stabilization.

Routine repeat-dose charcoal solely because GI motility is slowed is not established.

⸻

Whole-Bowel Irrigation

Whole-bowel irrigation is not routine.

It may occasionally be considered after a substantial sustained-release ingestion when:

• The patient is sufficiently stable
• Bowel function is adequate
• The airway is protected
• There is no obstruction, ileus, or perforation

Because antimuscarinic effects can impair GI motility, WBI may sometimes be impractical or inappropriate.

⸻

Extracorporeal Removal

Quinidine is generally poorly suited to routine extracorporeal removal because of its pharmacokinetic characteristics.

Historical suggestions that disopyramide should routinely undergo hemodialysis should also be interpreted cautiously.

Extracorporeal treatment is not the primary strategy for Class IA cardiotoxicity and should not delay:

• Sodium bicarbonate
• Dysrhythmia treatment
• Vasopressor support
• Electrolyte correction

⸻

Refractory Cardiovascular Collapse

Massive sodium-channel-blocker poisoning may rarely cause shock or dysrhythmia refractory to conventional therapy.

Selected severe cases may require advanced rescue measures such as VA-ECMO at an experienced center.

The older reference to “cardiac bypass” is better understood in modern practice as temporary extracorporeal circulatory support for potentially reversible poisoning.

⸻

Chronic Quinidine Adverse Effects

Therapeutic quinidine can rarely cause immune-mediated complications such as:

• Thrombocytopenia
• Hemolytic anemia
• Drug-induced lupus-like reactions

These are distinct from the acute electrophysiologic toxicity of overdose.

⸻

Drug Interactions

Risk increases when Class IA agents are combined with:

• Other QT-prolonging medications
• Other sodium-channel blockers
• Drugs altering their metabolism
• Drugs causing hypokalemia or hypomagnesemia

A medication review is therefore particularly important when toxicity occurs at apparently therapeutic dosing.

⸻

Differential Diagnosis

The combination of:

CNS toxicity + seizure + QRS widening

can also occur with:

• Tricyclic antidepressants
• Diphenhydramine and some other antihistamines
• Cocaine
• Flecainide/propafenone
• Chloroquine
• Other sodium-channel-blocking xenobiotics

QT prolongation and torsades have their own broad drug and electrolyte differential.

⸻

Monitoring

Significant poisoning requires:

• Continuous ECG
• Blood pressure monitoring
• Respiratory monitoring
• Serial electrolytes
• Renal function
• Serial assessment of QRS and QT

Severe cases also require monitoring for:

• Seizures
• Acidemia
• Shock
• End-organ hypoperfusion

⸻

Observation

A fixed 6-hour rule should not be applied universally.

Observation depends on:

• Agent
• Immediate- vs sustained-release formulation
• Amount
• ECG findings
• Symptoms
• Electrolytes
• Coingestants
• Clinical trajectory

Sustained-release products can produce delayed and prolonged toxicity.

⸻

Admission

Monitored inpatient care is appropriate for:

• QRS widening
• Significant QT prolongation
• Dysrhythmia
• Syncope concerning for dysrhythmia
• Hypotension
• Bradycardia/high-grade AV block
• Seizures
• Altered mental status
• Significant cinchonism
• Large sustained-release exposure

Severe cardiovascular instability warrants ICU care.

⸻

Pregnancy

Historical FDA pregnancy letter categories are obsolete.

Clinically significant poisoning during pregnancy should be managed according to maternal physiology, with priority given to:

• Airway
• Oxygenation
• Cardiac rhythm
• Blood pressure
• Seizure control

Maternal dysrhythmia and shock also threaten fetal perfusion.

⸻

Safeguarding

Rigid historical age cutoffs for neglect, abuse, or intentional poisoning are outdated.

Pediatric exposure should instead be assessed according to developmental capability, access, circumstances, history consistency, recurrent events, and other safeguarding concerns.

⸻

Prognosis

Mild poisoning may resolve with monitoring and supportive treatment.

Severe poisoning carries risk of:

• Ventricular dysrhythmia
• Torsades
• Cardiogenic/vasodilatory shock
• Seizures
• Respiratory failure
• Cardiac arrest
• Hypoxic brain injury

Outcome is strongly influenced by early recognition and correction of electrophysiologic toxicity.

⸻

Important Modernization of the Older Source

• Quinidine and disopyramide are now used much less commonly than historically.
• Class IA = sodium-channel blockade + potassium-channel blockade.
• Therefore, poisoning can produce both QRS widening and QT prolongation.
• Quinidine can cause cinchonism.
• Disopyramide has prominent antimuscarinic and negative-inotropic effects.
• Sodium bicarbonate is central when clinically important sodium-channel blockade is present.
• Correct K⁺ and Mg²⁺ aggressively when QT-related dysrhythmia risk is present.
• IV magnesium is central to torsades management.
• Overdrive pacing may help selected recurrent bradycardia-dependent torsades.
• Phenytoin/fosphenytoin is not routine modern therapy for Class IA cardiotoxicity or toxicologic seizures.
• Additional Class IA/IC sodium-channel blockers should generally be avoided.
• Norepinephrine is generally favored over routine dopamine-first treatment for persistent vasodilatory shock.
• Routine gastric lavage is obsolete.
• Repeated charcoal is not automatically indicated because of slowed GI motility.
• WBI has only a selective role in substantial sustained-release exposure.
• Drug concentrations should not delay ECG-directed treatment.
• Severe refractory cardiovascular collapse may warrant advanced extracorporeal circulatory support.

Key Points

• Class IA toxicity = Na⁺ blockade + K⁺ blockade.
• Na⁺ blockade → QRS widening and conduction slowing.
• K⁺ blockade → QT prolongation and torsades risk.
• Quinidine additionally causes cinchonism.
• Disopyramide has strong antimuscarinic and myocardial-depressant effects.
• Obtain an early ECG and continuously monitor significant poisoning.
• Sodium bicarbonate is first-line for important sodium-channel cardiotoxicity.
• Magnesium and electrolyte correction are central for torsades.
• Benzodiazepines are first-line for seizures.
• Avoid additional Class IA/IC agents that worsen conduction.
• Sustained-release formulations may cause delayed toxicity.
• There is no specific antidote.